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Anticoagulant therapy is essential for the prevention of risks associated with the formation of thrombus 
in patients after surgery, especially in orthopedics. Recently, new oral anticoagulants were introduced 
in the therapeutic arsenal. This fact is important, because the current drug of choice in clinical practice 
is enoxaparin, a low molecular weight heparin. As all injecting drugs, enoxaparin may reduce patients’ 
adherence to treatment by dissatisfaction with and resistance to the administration. This article reviews 
the available literature on the overall utility of these innovative medicines, approaching the pharmacology, 
the compared efficacy in relation to current agents, and the potential targets for new agents, as well as 
points to new trends in research and development. The article also contributes with a practical guide for 
use and recommendations to health professionals, especially focusing on the reversibility of hemorrhagic 
events, and discusses the importance of convenience/satisfaction of use, the cost of treatment, and the 
risk-benefit profile for patients.
Uniterms: Oral anticoagulants/use/patient compliance. Injectable anticoagulants/use/patient compliance. 
Anticoagulant therapy. Enoxaparin/use. Dabigatrana/use. Rivaroxabana/use. HPBM drugs/use.
A terapia anticoagulante é fundamental para a prevenção de riscos associados à formação de trombos 
em pacientes pós-cirúrgicos, principalmente em ortopedia. Recentemente, novos anticoagulantes orais 
foram introduzidos no arsenal terapêutico. Tal fato é importantíssimo, visto que o atual medicamento 
de primeira escolha na prática clínica é a enoxaparina, uma heparina de baixo peso molecular. Por ser 
de uso injetável, a enoxaparina pode diminuir a adesão do paciente ao tratamento, devido à insatisfação 
e à resistência quanto à via de administração. Este artigo revisa a literatura disponível sobre a utilidade 
total desses medicamentos inovadores ao abordar a farmacologia, a eficácia em comparação com os 
agentes atuais e os alvos potenciais para novos agentes, bem como aponta as novas tendências em 
pesquisa e desenvolvimento. O artigo também contribui com um guia prático de uso e recomendações 
aos profissionais de saúde, com um enfoque especial sobre a reversibilidade de eventos hemorrágicos 
e, finalmente, discute a importância da conveniência/satisfação de uso, o custo de tratamento e o perfil 
risco-benefício para o paciente.
Unitermos: Anticoagulantes orais/use/adesão ao tratamento. Anticoagulantes injetáveis/uso/adesão ao 
tratamento. Terapia anticoagulante. Enoxaparina/uso. Dabigatrana/uso. Rivaroxabana/uso. Fármacos 
HPBM/uso.
INTRODUCTION
All drug therapy needs to satisfy several require-
ments for good quality in health care. Safety and efficacy 
of drugs are extremely important, but not unique, proper-
ties to consider. Nowadays, a convenient treatment in-
creases adherence, and directly contributes to drug therapy 
success. In addition to these three requirements, the cost of 
treatment is also a constant concern, because a safe, effec-
tive and convenient therapy for the population is extremely 
limited, due to the high costs related (Wittkowsky, 2010).
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Thesearch for anticoagulants with acceptable ef-
ficacy and safety associated with patient compliance has 
been extensive, and several drugs were developed. A better 
understanding about the coagulation cascade allowed the 
development of drugs with action mechanisms different 
of those already existent, which directly act on previously 
unexplored coagulation factors. The evolution of recom-
binant DNA technology, in addition to the production of 
biopharmaceuticals on a large scale, promoted the expan-
sion inthe number of anticoagulant drug prototypes, based 
on substances found in biological systems (Walsh, 2007).
Despite the extensive use of heparin and low mo-
lecular weight heparins (LMWHs) in thromboprophylaxis 
after orthopedic surgeries, the subcutaneous administra-
tion also decreases patient adherence to treatment, which 
is viewed with concern by health professionals involved 
in drug therapy. Therefore, the development of oral anti-
coagulants which are able to replace heparin and LMWHs, 
with improved safety and efficacy compared to warfarin, 
is a matter of great expectation. 
This review article aims to inform health profes-
sionals about the development of anticoagulant drugs and 
their use in patients who underwent orthopedic surgeries. 
Additionally, this paper comprises the relevance of new 
oral anticoagulants) as dabigatran and rivaroxaban, for-
mulating a practical guide for use, as well as new trends 
in research and development.
Pharmacology and potential targets for new 
agents
Hemostasis, a crucial event to life, is defined as the 
interruption of blood loss by injured vessels. Blood must 
remain fluid within the vasculature, and still quickly co-
agulate when exposed to non-endothelial surfaces, such as 
regions of vascular injuries. When intravascular thrombi 
are formed, there is an activation of the fibrinolysis system 
in order to restore the normal blood flow. Under normal 
conditions, a delicate balance is established with the pur-
pose of avoiding thrombosis and bleeding. This balance is 
obtained by physiological fibrinolysis, without excessive 
pathological fibrigenolysis. In the first step of thrombus 
formation, platelets adhere to macromolecules in the 
subendothelial regions of the injured blood vessel, and 
then aggregate to form a primary hemostatic cover. Then, 
platelets stimulate local activation of plasma coagulation 
factors, resulting at the end in a fibrin clot. Later, as the 
injury is healed, both the platelet aggregate and the fibrin 
clot are destroyed (Majerus, Tollefsen, 2006).
The conversion of fibrinogen, a floating soluble pep-
tide, into insoluble threads of fibrin is catalysed by throm-
bin (factor IIa), and it is the main event of the coagulation 
cascade. Moreover, thrombin activates factor XIII as well, 
which crosslinks the fibrin fragments and consequently 
stabilizes the clot. Fibrin formation involves a complex 
cascade of reactions, whose components (factors) are pres-
ent in blood as inactive precursors, but can be activated by 
enzymatic proteolysis. The activation of a small amount of 
one factor catalyses the activation of larger quantities of 
the following factor. That cascade provides a sophisticated 
mechanism of signal amplification (Rang et al., 2003). 
However, under normal conditions, such amplification is 
carefully controlled by physiological inhibitors such as 
inhibitor of tissue factor pathway, antithrombin III (ATIII), 
an inhibitor of thrombin, and activated protein Can inhibi-
tor of factors VIIIa and Va (Breitenstein, Tanner, Lüscher, 
2010). There are two pathways which culminate in fibrin 
formation: 1) the intrinsic pathway - all its components 
are present in the blood; and 2) extrinsic pathway – some 
factors are external to the vasculature. Both finally activate 
the common pathway (Figure 1).
Understanding of the coagulation cascade allowed 
the development of anticoagulant drugs, or, in other words, 
substances used to prevent unwanted blood clotting, 
mainly when endogenous anticoagulant mechanisms are 
defective or insufficient. Some severe pathological condi-
tions such as venous thromboembolism (VTE), deep vein 
thrombosis (DVT), and pulmonary embolism (PE) require 
the therapeutic use, in the short or long term, of this class 
of drugs. Anticoagulant therapy is also recommended for 
the long-term prevention of ischemic stroke in patients 
with atrial fibrillation and for the prevention of recurrent 
myocardial infarction in patients with acute coronary 
syndromes (ACSs), such as unstable angina or non-ST 
elevated myocardial infarction (Turpie, 2007).
Since the discovery of heparin, in 1916, the de-
velopment and use of these drugs in the prevention and 
treatment of thromboembolic events have been growing 
worldwide, especially with population aging. For instance, 
patients who are undergoing some surgeries such as total 
hip arthroplasty (THA) and total knee arthroplasty (TKA) 
have high risk of developing VTE and proximal and total 
DVT. This threat has decreased significantly in the last 20 
years, with the introduction of thromboprophylaxis, which 
is currently performed using oral or parenteral anticoagu-
lant drugs (Weitz, Hirsh, Samama, 2008).
 Nowadays, the most common available antico-
agulant drugs include the heparinoids, unfractionated 
heparin (UFH), and low molecular weight heparins (LM-
WHs) such as enoxaparin, dalteparin and tinzaparin, which 
emerged due to their greater safety, efficacy and conve-
nience of administration when compared to UFH. Other 
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FIGURE 1 - Classic anticoagulant drugs and their targets in the coagulation cascade (Lassen, Laux, 2008).
FIGURE 2 - Targets for new anticoagulant drugs in the coagulation cascade (Turpie, 2007).
important drugs are the vitamin K antagonists (VKA), 
such as warfarin, and indirect inhibitors (because they 
require the action of ATIII) of FXa, such as fondaparinux 
and idraparinux (Figure 1).
However, these therapies have some important 
limitations, such as the risk of thrombocytopenia, the 
parenteral use of heparins and fondaparinux, the monitor-
ing need, low therapeutic indexes, and drug interactions 
with warfarin, which underlined the need to develop 
new agents. Due to this situation, new oral drugs were 
recently produced. As examples of this type of drugs, it 
can be pointed out the direct thrombin inhibitor (with 
independent action of ATIII) dabigatran, and Factor Xa 
inhibitorssuch as rivaroxaban and apixaban. Ximela-
gatran, another direct thrombin inhibitor, was removed 
from the European Pharmacopoeia, due to liver toxicity 
induced by this substance (Samama, Gerotziafas, 2010). 
Other molecules, even in studies, appear as candidates 
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for anticoagulant therapies with different targets in the 
coagulation cascade (Figure 2).
There are important features about the new antico-
agulants, which need to be discussed. One example is their 
mechanisms of action, involving the direct or indirect in-
hibition of factors Xa and IIa, target specificities, intensity 
of anticoagulation, type of target connection, and potential 
antigen actions. There is a disagreement among experts 
about the drugs that would bring a better risk-benefit ratio, 
because only a small number of trials were done.
One limitation to the clinical evaluation of new an-
ticoagulants is the low sensitivity of current coagulation 
tests, which lead to an incorrect evaluation of the risk of 
bleeding related to each drug. For instance, fondaparinux 
and idraparinux hardly change the prothrombin time (PT) 
and the activated partial thromboplastin time (APTT), 
even when administered in doses so high that they trig-
ger hemorrhage episodes. Prolonged PT induced by 
anticoagulant drugs as rivaroxaban cannot be expressed 
by the international normalized ratio (INR). It is applied 
only for the VKAs, because an INR enhanced by a new 
anticoagulant (inhibitor of only one factor of the coagula-
tion cascade) can not be compared to an INR of a VKA 
(inhibitor of several factors of this cascade).
It is necessary to investigate the reasons that lead 
to fondaparinux/idraparinux and rivaroxaban be or not 
different in increasing PT. A possible reason is that rivar-
oxaban inhibits free Factor Xa and also Factor Xa linked 
to phospholipids within the prothrombinase complex, 
while fondaparinux and idraparinux only inhibit free 
Factor Xa.
Some other properties should to be investigated, as 
the possibility of cardiovascular complications related to 
the rebound effect of coagulation with the discontinuation 
of treatment and, especially, the existence of an antidote, 
preferably specific for drugs with long half-life. An impor-
tant stage of clinical trials is to determine the therapeutic 
window, especially for drugs such as dabigatran, which 
displays a strong interdependence between the concentra-
tion of the drug and clinical response based on the num-
ber of occurrences of thromboembolic events (Samama, 
Gerotziafas, 2010).
Direct inhibitors of Factor Xa for parenteral use
Fondaparinux is a synthetic pentassaccharide simi-
lar to that of heparin, with half-life of approximately 17 
hours, increasing to approximately 20 hours in elderly 
people. This long half-life allows a regimen of just one 
daily subcutaneous administration. In surgical patients, the 
therapeutic dose is 2.5 mg, while in patients treating severe 
DVT or PE the therapeutic dose may reach 7.5 mg, which 
is considered safe for patients between 50 and 100 kg. For 
patients less than 50 kg and over 100 kg, daily doses of 5 
mg and 10 mg are respectively suggested.
Idraparinux is a synthetic pentassaccharide similar 
to fondaparinux; however, idraparinux have a greater 
anticoagulant activity, mainly due to its greater affinity 
for antithrombin and its long half-life (80 to 130 hours). 
These properties allow it to be administered subcutane-
ously, just once a week. Clinical trials have shown its 
efficacy and safety for treatment of DVT only, although 
its anticoagulant effect after discontinuation of treatment 
was observed. Studies about its use in the treatment of PE 
did not produce good results due to the recurrence of PE 
in the first five days of treatment.
DX-9065a is a nonpeptidic direct inhibitor of Factor 
Xa that is administered parentally. It has a dose-dependent 
half-life that ranges from 40 minutes to 5 hours, and is 
cleared by kidneys. This drug was evaluated in patients 
with non-ST-elevation ACS, and in patients undergoing 
percutaneous coronary intervention. In a trial on ACS, 402 
patients were randomized to weight-adjusted heparin or to 
low- or high-dose DX-9065a. There were no significant 
decreases in deaths, myocardial infarction, need for urgent 
revascularization, or ischemia. Cases of serious bleeding 
occurred in both groups of patients, without statistically 
significant differences (Weitz, Hirsh, Samama, 2008).
Otamixaban, a non-competitive inhibitor of FXa, is 
administered intravenously and has a half-life of 2–3 hours. 
It is excreted unchanged in urine, whereas metabolites 
appear in the feces. A phase II study compared a 24-hour 
otamixaban infusion with placebo in patients with stable 
coronary artery disease. The addition of otamixaban to 
usual medications did not cause bleeding, and otamixaban 
produced a rapid and sustained increase in anti-factor Xa 
activity. A phase II trial comparing otamixaban with heparin 
in patients undergoing nonurgent percutaneous coronary in-
terventions demonstrated greater reductions in the levels of 
prothrombin fragment with otamixaban than with heparin; 
no difference in the rate of major bleeding was observed.
Direct inhibitors of Factor Xa for oral use
The advantages of oral anticoagulants compared 
to parenteral are obvious, mainly considering the time 
of treatment, which sometimes lasts weeks, months, and 
even years. Among the new oral anticoagulants, there are 
rivaroxaban, apixaban and edoxaban, all of which have 
molecular mass of approximately 500 Da. These com-
pounds potentially and selectively inhibit Factor Xa and, 
in increasing doses, increase PT more than PTTA.
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Rivaroxaban is quickly absorbed, reaches its maxi-
mum blood concentration 2 to 4 hours after administration, 
has oral bioavailability of 80%, and is cleared mainly by 
kidneys. In Europe, this drug is indicated for primary pre-
vention of thrombotic events subsequent to THA and TKA 
surgeries in adults. Its use in preventing stroke in patients 
with non-valvular atrial fibrillation is still under investiga-
tion. Clinical studies comparing the efficacy of rivaroxa-
ban and enoxaparin in reducing cases of VTE after THA 
and TKA surgeries showed a significant reduction of 50% 
in the cases of VTE between groups treated with rivar-
oxaban when compared with enoxaparin-treated groups. 
There was no significant difference between groups when 
cases of bleeding were compared. Moreover, there is still 
a discussion about the risk of hemorrhage associated with 
treatment with rivaroxaban, because studies conducted by 
two different research groups reached opposite conclu-
sions. The rebound phenomenon after discontinuation of 
cardiovascular treatment with rivaroxaban should be fur-
ther investigated, because there is some degree of concern 
expressed in literature.
Direct inhibitors of thrombin
Direct inhibitors of thrombin are different from 
heparins, whose anticoagulant activities are mediated by 
antithrombin. Some examples of this type of drugs are hir-
udin, its derivative bivalirudin, argatoban, ximelagatran, 
and dabigatran, which is discussed below.
Dabigatran is orally administered as a prodrug - dab-
igatran etexilate - and was initially studied for prophylaxis 
after THA and THK surgeries, and then for the treatment 
of acute episodes of VTE. Its use in the prevention of 
VTE cases and stroke in patients with non-valvular atrial 
fibrillation is still also under clinical investigation. A clini-
cal study showed that dabigatran was not as efficient as 
enoxaparin in preventing VTE, due to high rates of distal 
DVT, even with equivalent rates of VTE. About DVT and 
PE rates and mortality due to VTE, there was no significant 
difference among the drugs analyzed. Even with no reports 
of hepatic toxicity, it isnot recommended to administer 
dabigatran in patients with severe liver failure or elevated 
liver enzymes or bilirubin. The risk-benefit ratio in elderly 
patients predisposed to cardiovascular events or with 
renal failure was considered satisfactory (Weitz, Hirsh, 
Samama, 2008).
Inhibitors of Factor Va
Factor Va is the main target of activated protein C, 
which acts as an anticoagulant substance by proteolytic 
degradation and inactivation of factor Va, a key cofactor 
in thrombin generation.
ART-123, a recombinant analogue of the extracel-
lular domain of thrombomodulin, binds thrombin and 
enhances its capacity to activate protein C. This drug has 
nearly 100% bioavailability after subcutaneous admin-
istration, and a half-life of 2 to 3 days. Plans for further 
development of this agent are uncertain8.
Drotrecogin, a recombinant form of activated pro-
tein C, is approved for treatment of patients with severe 
sepsis. Approval for this indication was based on a trial 
comparing drotrecogin with placebo in 1,690 patients 
with severe sepsis. In this study, drotrecogin significantly 
reduced the mortality of patients in 28 days. However, 
other two clinical trials were stopped prematurely, due to 
lack of efficacy and the potential to cause harm because 
of bleeding8.
Inhibitors of Factor VIIa
Drugs that target the factor VIIa inhibit the initiation 
of coagulation. Only parenteral agents in this category 
have reached phase II or III clinical testing. These include 
tifacogin, recombinant nematode anticoagulant peptide 
(NAPc2) and inactive factor VIIa (factor VIIai).
Ticofagin, a recombinant form of tissue factory 
pathway inhibitor expressed in Saccharomyces cerevisae, 
has been evaluated in patients with sepsis. This drug has 
a half-life of minutes, necessitates intravenous infusion, 
and is cleared by liver. In a phase II trial, 44210 sepsis 
patients were randomized to receive one or two doses of 
tifacogin by continuous infusion or placebo for 4 days, 
resulting in 20% relative reduction in 28-day mortality. 
Differences about major bleeding were not statistically 
significant. Based on these results, a phase III trial that 
compared tifacogin with placebo in severe sepsis patients 
was performed. The primary end point, 28-day mortality, 
was similar with tifacogin and placebo, while the rate of 
bleeding was significantly higher with tifacogin (Weitz, 
Hirsh, Samama, 2008).
Recombinant NAPc2, an 85-amino acid polypeptide 
originally isolated from the canine hookworm, Ancylos-
toma caninum, is expressed in yeast. This substance binds 
to a noncatalytic site on factor X or factor Xa. Once bound 
to factor Xa, the NAPc2/factor Xa complex inhibits tissue 
factor-bound factor VIIa. Because it binds factor X with 
high affinity, NAPc2 has a half-life of approximately 50 
hours after subcutaneous injection. Consequently, the drug 
can be administered on alternate days.
Initial clinical studies focusing on thromboprophy-
laxis showed this drug has the same efficacy and safety 
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when compared with LMWHs. However, prospective 
randomized studies are needed to confirm these findings. 
After these promising results, further studies focusing on 
the application of this drug on arterial thrombosis and as 
a substitute for heparin in patients undergoing PCI are 
being conducted.
In turn, recombinant factor VIIa, which has its ac-
tive site irreversibly blocked, competes with factor VIIa 
for tissue factor binding, thereby attenuating the initiation 
of coagulation by the factor VIIa/tissue factor complex. 
Based on promising results in animal models of throm-
bosis, factor VIIai, with or without adjunctive heparin, 
was compared with heparin alone in patients undergoing 
elective PCI. Factor VIIai, with or without adjunctive 
heparin, produced no significant reduction in the primary 
end point, a composite of death, myocardial infarction, 
need for urgent revascularization, abrupt vessel closure, 
use of Glycoprotein IIb/IIIa antagonists or heparin at day 
7 or at hospital discharge. Rates of major bleeding were 
similar with factor VIIai and heparin. Because of these 
disappointing results, factor VIIai has not been developed 
further for treatment of arterial thrombosis (Weitz, Hirsh, 
Samama, 2008).
Inhibitors of Factor IXa
Both parenteral and oral factor IXa inhibitors are 
under development. The parenteral factor IXa inhibitor is 
an RNA aptamer (designated RB006) that binds factor IXa 
with high affinity. In phase I studies, this aptamer produced 
rapid anticoagulation as evidenced by a dose-dependent 
prolongation of the APTT. A positive aspect of RB006 is 
its potential for rapid neutralization by a complementary 
oligonucleotide (designated RB007). This drug-antidote 
pair is being developed for use in cardiopulmonary bypass 
surgery, or other indications where rapid anticoagulant re-
versal may be beneficial. An orally active direct factor IXa 
inhibitor also has been developed. Designated TTP889, 
this agent completed a phase IIa clinical trial that was 
negative (Weitz, Hirsh, Samama, 2008).
Practical Guide for Use of Dabigatran and 
Rivaroxaban
The search for an ideal anticoagulant aims at find-
ing an oral agentthat, unlike warfarin, does not require a 
routine coagulation monitoring. Moreover, this ideal drug 
must have a wide therapeutic index, with low variability 
within and among patients; shall not have any interactions 
with other drugs or foods; shall have the ability of use in 
monotherapy, with no overlapping of parenteral anticoagu-
lant drug, for use in acute and chronic thromboembolism, 
in hospital or at home, with an adequate safety profile; 
shall have a minimum risk of adverse effects; and, finally, 
its anticoagulant effect shall be easily reversible, with or 
without an antidote.
Assays
Among the new oral anticoagulants, dabigatran and 
rivaroxaban will be the objects of study of this practical 
guide. Indeed, a theoretic discussion about the superiority 
of use of factor Xa rivaroxaban versus factor IIa dabigatran 
as a target for anticoagulant therapy was always present in 
related research. For phase III clinical trials of dabigatran 
for TKA and THA, comparative studies with enoxaparin 
– RE-MOBILIZE (TKA, n = 2,615), RE-MODEL (TKA, 
n = 2,101), and RE-NOVATE (THA, n = 3,494) – had 
very distinct demonstrative analyses. In RE-MOBILIZE 
(TKA, n = 2,615), dabigatran was inferior to enoxaparin; 
in the other studies, equivalence between these drugs was 
observed. However, from a meta-analysis of available 
assays, the immediate conclusion is that there was no dif-
ference between dabigatran and enoxaparin in any of the 
endpoints analyzed. As for rivaroxaban, phase III clinical 
trials comparing it to enoxaparin – RECORD 1 (THA, n = 
4,541), RECORD 2 (THA, n = 2,509), RECORD 3 (TKA, 
n = 2,531) and RECORD 4 (TKA, n = 3,148) – showed su-
periority of rivaroxaban to enoxaparin, and a meta-analysis 
confirmed these results (Wittkowsky, 2010).
Pharmacokinetic parameters
Pharmacokinetic parameters provide valuable infor-
mation about these oral anticoagulants, as shown in Table 
I. Extensive discussions about these parameters are not 
the purpose of this paper. Instead, by providing a quick 
source of information, a discussion about the relevance 
of this review is intended.
Dabigatran exetilate, the prodrug of dabigatran, 
requires an acid environment for absorption. Each drug 
capsule contains multiple pellets that have a tartaric acid 
core that creates an acidic microenvironment to improve 
dissolution and absorption of dabigatran exetilate, inde-
pendent of gastric pH. Antacids and H2 blockers have no 
effect on this system or on the absorption of dabigatran 
etexilate. Proton pump inhibitors reduce the average area 
under the serum concentration versus time curve (AUC) 
of dabigatran by 22% and the average maximum serum 
concentration (Cmax) by 33%, but these changes are not 
considered clinically relevant. Food simply delays the time 
to Cmax, and thus dabigatran exetilate can be taken orally 
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with or without meals. In comparison, food not only delays 
the time to Cmax for rivaroxaban, it also increases the 
AUC by 28% and the Cmax by 41%. In addition, adminis-
tration with food appears to reduce interpatient variability 
of AUC and Cmax, thus increasing the predictability of 
plasma drug concentrations. Thus, it is recommended 
that rivaroxaban be taken with meals or within 2 hours 
after meals. Antacids and H2 blockers have no impact on 
rivaroxaban, but no information is currently available 
about the effect of proton pump inhibitors. The effect of 
food, antacids, H2 blockers and proton pump inhibitors on 
apixaban has not yet been reported (Wittkowsky, 2010).
About renal function, rivaroxaban shall be used with 
caution in patients with creatinine clearance (Clcr) of less 
than 30 mL/min, and is not recommended in patients with 
Clcr of less than 15 mL/min. There is much more to be 
learned about the safety of these agents in patients with 
mild moderate and severe renal impairment, as well as in 
those with changing renal function (Wittkowsky, 2010).
On the other hand, dabigatran appears to have less 
drug interaction potential than rivaroxaban, because its 
metabolism does not involve the cytochrome P450 system 
(CYP). Thus, in order to understand the potential of the 
new oral anticoagulants to generate drug interaction, we 
need to understand the transport of P-glycoprotein (P-gp). 
P-gp functions as an efflux pump to prevent the absorp-
tion or increase the renal secretion of certain drugs known 
as p-GP substrates. Inhibitors of P-gp will increase the 
serum concentrations of P-gp substrates, and inducers of 
P-gp will reduce the serum concentrations of P-gp. Both 
dabigatran and rivaroxaban appear to be P-gp substrates. 
A review about dabigatran conducted by the European 
Medicines Agency states that amiodarone, an inhibitor 
of P-gp, increases the AUC of dabigatran by 60% and 
the Cmax by 50%, and also recommends that the dose 
of dabigatran be reduced to 150 mg daily in patients 
taking it concurrently with amiodarone. It further states 
that care must be taken with strong p-GP inhibitors like 
verapamil, clarithomycin and others, while quinidine is 
contraindicated. Potent p-GP inducers such as rifampicin 
or St John’s wort (Hypericum perforatum) may reduce 
the systemic exposure of dabigatran. Caution is advised 
when co-administering these medicinal products. There 
appears to be significant interplay between CYP3A4 and 
p-GP, such that they appear to act synergistically to limit 
oral drug bioavailability. Thus, drugs that are substrates 
for both CYP3A4 and p-GP often have low bioavailabil-
ity. Moreover, drug interactions involving both CYP3A4 
and p-GP inhibition or induction may be more significant 
than those affecting one or the other system alone. Of the 
four drugs known to inhibit rivaroxaban metabolism by 
inhibiting CYP3A4, ketoconazole and ritonavir do so to 
the greatest extent. Those agents are strong inhibitors of 
both CYP3A4 and p-GP. Comparatively, erythromycin 
is a moderate inhibitor of both CYP3A4 and p-GP, while 
clarithromycin is a strong CYP3A4 and a moderate p-GP 
inhibitor (Wittkowsky, 2010).
Hemorrhage complications
No differences were found between dabigatran and 
enoxaparin, and between rivaroxaban and enoxaparin, in 
any category of bleeding, despite some inconsistencies 
among trials. The management of bleeding complica-
tions associated with traditional anticoagulants, including 
warfarin, UFH and LMWHs, is aided by the availability 
TABLE I - Comparative pharmacokinetic properties of dabigatran and rivaroxaban
Pharmacokinetic parameter/Drug Dabigatran Rivaroxaban
Molecular weight 628 Da 436 Da
Protein binding 35% >90%
Vd 60-70L 50L
Dialyzable Yes Not expected
Tmax 1,25-3h 2,4h
T 1/2 12-14h 5-9h
Activation Prodrug dabigatran etexilate converted to 
active drug dabigatran via hydrolysis 
None
Renal excretion of unchanged drug 80% 36%
Metabolism Conjugation Oxidation (via CYP3A4 [18%] and 
CYP2J2 [14%] and hydrolysis)
Vd: Volume of distribution; Tmax: Time to maximum serum concentration; T 1/2: time of elimination half-life. (Wittkowsky, 2010).
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of antidotes (vitamin K, protamine), laboratory tests to 
assess the level of anticoagulation (INR, aPTT, antiXa 
activity), and clinical guidelines. Comparatively, there is 
little information available at present to guide management 
of bleeding complications associated with the new oral 
anticoagulants nowadays. No specific antidotes are avail-
able and there is little information regarding the potential 
role of blood products, antifibrinolytic agents (aminoca-
proic acid, tranexamic acid) or prohemostatic agents, like 
recombinant factor VIIa, to manage bleeding associated 
with dabigatran or rivaroxaban. Methods to accelerate 
removal of these drugs from plasma using dialysis, hemo-
perfusion or plasmapheresis have yet to be investigated 
(Wittkowsky, 2010; Garcia, Libby, Crowther, 2010).
Evidence-based strategies for reversal of bleed-
ing associated with new anticoagulants are not avail-
able. Although it may be necessary to intercede, it will 
be infrequently, because all drugs have short half-life 
times. To many clinicians, the lack of an antidote or an 
evidence-based strategy to manage bleeding may be a 
disadvantage. Principles for management of bleeding re-
lated to anticoagulants (with specific focus on new agents) 
have been described, at least in an in vitro study, where a 
potential strategy for further investigation was identified 
(Wittkowsky, 2010; Garcia, Libby, Crowther, 2010).
Innovative drugs in development
In addition to new therapeutic options present here, 
other anticoagulant drugs are still in development, or un-
dergoing clinical trials. Although some of them have not 
been developed for use in VTE, DVT or PE, their applica-
tions in these pathologies should be evaluated.
In the class of VKA, tecarfarin appears as an impor-
tant option for treatment of patients with atrial fibrillation, 
because it is less susceptible to drug interactions due to 
its metabolism by carboxylesterases, instead of warfarin, 
whose biotransformation is mediated by enzymes of P450 
cytochrome system. This metabolic selectivity is possible 
due to the fact that tecarfarin is a single enantiomer. A 
phase II clinical assay proposed 15,6 mg as mean daily 
dose, which was well tolerated by individuals participating 
of the trial (Ellis et al., 2010).
Recombinant human antithrombin (RHA) is a par-
ticularly important drug for patients who have hereditary 
deficiency of antithrombin production, and consequently 
need this medication to avoid thromboembolic events. 
RHA is administered together with heparinoids, and in-
creases anticoagulant activity from 300 to 1,000 times. Its 
production is made through the use of transgenic goats, in 
which the human antithrombin gene is fused with regula-
tory genes of mammary glands, producing about 2g of 
RHA per L of milk (Cada, Levien, Baker, 2009).
In the universe of antidotes used to control bleeding, 
a new therapeutic approach is the prothrombin complex 
concentrate, containing factors II, VII, IX and X, in ad-
dition to anticoagulant proteins C and S. This complex 
proved to be effective in reversing anticoagulation gener-
ated by administration of VKA (Pabinger et al., 2007).
Recommendations
Drug therapy in order to improve people’s health 
does not end in the administration of a prescribed medica-
tion. Therapeutic follow-up based on clinical response and 
on the opinion of the patient regarding his clinical condi-
tion is decisive to evaluate the effectiveness of a drug. 
In this sense, pharmacovigilance plays an essential role, 
because a newly marketed drug still has not all necessary 
information, like drug interactions and adverse events. 
This condition comes from the limitations of clinical 
studies of phases I, II and III, which involve only selected 
patients, limited by both age and weight, with no other 
pathologies and not using other drugs.
In the first years of post-marketing drugs, it is ex-
tremely important to evaluate their efficacy and safety, 
because, during this period, several side effects and 
drug interactions of real importance but previously un-
known are discovered. In addition, the description about 
medicines may change in the leaflets, and it may even be 
withdrawn from market, according to new data reported.
Responsible health professionals must always search 
information about drugs related to their work, in order that 
their professional performance can indeed improve the 
health and, consequently, the quality of life of population.
The total utility of all new anticoagulants will de-
pend on many factors, including effectiveness compared 
with current agents, the cost, the benefit-risk profile, the 
reversibility of hemorrhagic events, convenience, and 
patient satisfaction. Generally, the results of safety and 
efficacy in clinical practice do not correspond to the 
controlled clinical trials of new anticoagulants, due to the 
several parameters that must be carefully observed;for 
example, unpredictable drug interactions, renal failure, 
obesity, a long half-life elimination of these agents, inabil-
ity to monitor them practically and routinely, incapacity 
to quickly reverse their effects at the time of an emerging 
bleeding or invasive procedures, and other patient char-
acteristics that may have a considerable influence on the 
results, limiting the use of these new substances. However, 
at moments such as prophylaxis after prolonged orthope-
dic surgery, these agents may replace LMWHs, and its 
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oral administration and its cost can provide a persuasive 
argument for their use. Therefore, the entire team involved 
in drug therapy should be encouraged to carefully evaluate 
not only the dose and duration of therapy with these new 
anticoagulants, but also to monitor adverse effects and 
drug interactions in order to enjoy the conclusions about 
the real advantage of this therapy (Wittkowsky, 2010; 
Garcia, Libby, Crowther, 2010). 
CONCLUSION
Currently, HPBM are the drugs of first choice for 
prophylactic treatment of DVT and VTE in orthopedic, 
multiple trauma and immobilized patients. These drugs 
have more effective and safety based on the widely studied 
clinical practice.
It is unquestionable that anticoagulant therapy has 
experienced many advances, particularly by integrating 
two new drugs with high level of importance. Undoubted-
ly, the new oral anticoagulants are likely to increase patient 
compliance compared with the injectable anticoagulant 
treatment. As discussed, clinical trials demonstrated non-
inferiority compared to enoxaparin in patients following 
orthopedic surgeries. In the future, with the expansion of 
the studies, rivaroxaban and dabigatran seem to emerge 
as potential drugs of choice for anticoagulation therapy.
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